Hospital Clínic Barcelona’s Diabetes Unit has been qualified by the European INNODIA network as a clinical trial site (CTS), which will allow it to participate in international clinical trials for type 1 diabetes. This accreditation strengthens IDIBAPS-Hospital Clínic Barcelona’s commitment to translational research and provides more access to innovative therapies for the disease.
INNODIA is a European network that aims to accelerate the development of new treatments and promote therapies that improve the quality of life of people with type 1 diabetes. Its services include the qualification of clinical trial sites, facilitating cooperation between hospitals, patients and the healthcare and pharmaceutical industries.
IDIBAPS was accepted as an associate member of INNODIA in 2024, a key step now further supported by the Diabetes Unit’s qualification as a clinical trial site. ‘Hospital Clínic’s Diabetes Unit is a multidisciplinary and cross-sectional structure that integrates care, education and innovation, with research as its central focus’, explains Marga Giménez, the head of the unit.
According to Ignacio Conget, a researcher in the IDIBAPS research group Translational research in diabetes, lipids and obesity, the qualification presents an opportunity to make progress in preventing, diagnosing and treating type 1 diabetes: ‘Our ultimate goal is to improve the quality of life of people living with this disease’.
Image: From left to right: Antonio Jesús Blanco, Ignacio Conget, Montse Granados and Margarita Giménez.
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
A paper published in Alzheimer’s & Dementia: The Journal of the Alzh...
